title: A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome.
abstract: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, oligo-/anovulation, and polycystic ovarian morphology and is a complex endocrine disorder that also presents with features of the metabolic syndrome, including obesity, insulin resistance, and dyslipidemia. These latter symptoms form cardiometabolic risk factors predisposing individuals to the development of type 2 diabetes and cardiovascular disease (CVD). To date, animal models to study PCOS in the context of the metabolic syndrome and CVD risk have been lacking. The aim of this study was to investigate the JCR:LA-cp rodent as an animal model of PCOS associated with the metabolic syndrome. Metabolic indices were measured at 6 and 12 wk, and reproductive parameters including ovarian morphology and estrous cyclicity were assessed at 12 wk or adulthood. At 6 wk of age, the cp/cp genotype of the JCR:LA-cp strain developed visceral obesity, insulin resistance, and dyslipidemia (hypertriglyceridemia and hypercholesterolemia) compared with control animals. Serum testosterone concentrations were not significantly different between groups at 6 wk of age. However, at 12 wk, the cp/cp genotype had higher serum testosterone concentrations, compared with control animals, and presented with oligoovulation, a decreased number of corpora lutea, and an increased number of total follicles, in particular atretic and cystic follicles. The cardiometabolic risk factors in the cp/cp animals were exacerbated at 12 wk including obesity, insulin resistance, and dyslipidemia. The results of this study demonstrate that the JCR:LA-cp rodent may be a useful PCOS-like model to study early mechanisms involved in the etiology of cardiometabolic risk factors in the context of both PCOS and the metabolic syndrome.
authors.affiliation: Alberta Institute for Human Nutrition, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Danni
authors.initials: D
authors.lastname: Shi
authors.forename: Michael K
authors.initials: MK
authors.lastname: Dyck
authors.forename: Richard R E
authors.initials: RR
authors.lastname: Uwiera
authors.forename: Jim C
authors.initials: JC
authors.lastname: Russell
authors.forename: Spencer D
authors.initials: SD
authors.lastname: Proctor
authors.forename: Donna F
authors.initials: DF
authors.lastname: Vine
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004195:Disease Models, Animal; D030762:Estrous Cycle / Q000502:physiology; D005215:Fasting / Q000097:blood; D005260:Female; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D050152:Intra-Abdominal Fat / Q000033:anatomy & histology; D020738:Leptin / Q000097:blood; D008099:Liver / Q000378:metabolism; D024821:Metabolic Syndrome / Q000150:complications* / Q000378:metabolism; D010053:Ovary / Q000033:anatomy & histology; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000378:metabolism; D051381:Rats; D054411:Receptors, Leptin / Q000235:genetics*; D012307:Risk Factors; D014280:Triglycerides / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D054411:Receptors, Leptin; D014280:Triglycerides